The World's First
Universal Oral Antidote
Our broad-spectrum oral therapy, designed for rapid, accessible snakebite treatment, enabling earlier intervention and improving outcomes worldwide.
Collaborators and partners
A devastating crisis the world keeps overlooking
Snakebite envenoming kills tens of thousands every year, mostly in rural regions where antivenom is unavailable, unaffordable or simply too late.
0M
Snakebites annually
0K
Deaths per year
0K
Life-changing disabilities
0%
Of countries with venomous snakes
An immediate pre-hospital approach
Traditional antivenom has barely changed since the 1890s and only works in hospital. Our oral combination therapy is designed for the critical first hours, wherever a bite happens.
Immediate intervention
Minimal delay between bite and treatment, addressing the critical pre-hospital window.
Broad-spectrum coverage
Multiple toxins targeted for broader protection across medically significant species.
Oral and field-ready
No IV, no cold chain. A format that reaches the most remote communities.
Protect tissue, preserve function
Designed to prevent the local tissue damage that existing antivenom cannot reach, and that causes lifelong disability in survivors.
Better outcomes
Early prevention of both local and systemic effects, improving survival and recovery.
Supporting the WHO 2030 Goal
The World Health Organisation aims to halve the global burden of snakebite envenoming by 2030. The burden falls hardest on communities in South Asia, sub-Saharan Africa and Latin America.* Antigenika is developing a novel oral therapy to enable treatment immediately, wherever a bite occurs.
* Sources: WHO, eLife, Nature Comms, PLOS NTD.
Led by World-Class Experts
Our team brings together decades of experience in venom research, pharmaceutical development and global health.
The science behind a new generation of snakebite treatment
Discover how our oral combination therapy targets multiple venom pathways to protect lives in the critical window before hospital care is available.
Back the breakthrough. Redefine treatment.
Antigenika sits at the intersection of high unmet clinical need, strong scientific innovation and scalable global impact. Partners, investors and press: we’d like to hear from you.